A biomedical company originating from Oxford University has secured a five hundred thousand dollar investment from one of its shareholders, enabling continued research activities.
Dr Tony Coombs, chairman of Oxford Vacmedix UK Limited, which operates from Oxford Science Park, expressed satisfaction with the capital injection received from the firm’s second-largest shareholder.
According to Dr Coombs, the funding ensures that Oxford Vacmedix maintains solvency and can satisfy all outstanding obligations, with the entire workforce retaining their positions.
The announcement preceded a previously scheduled gathering of shareholders and creditors originally set for September 1st, at which the future of the university spinout was to be determined.
The investment has rendered that meeting unnecessary, permitting operations to proceed uninterrupted.
Oxford Vacmedix represents a commercial venture established by the University of Oxford to advance therapeutic agents for cancer treatment, originating from discoveries made by Professor Shisong Jiang within the Department of Oncology.
The proprietary methodology employs Recombinant Overlapping Peptides, a novel approach to administering immunotherapy that has emerged as a significant priority in cancer management.
The technology enhances delivery efficiency, therapeutic outcomes, and cost-effectiveness.
Immunotherapy functions by stimulating the immune system to directly target and attack tumour cells, thereby diminishing reliance on invasive interventions such as chemotherapy and radiation therapy.
The enterprise was established in September 2012, with preclinical development commencing in March 2018 following a twelve and a half million dollar investment.
Clinical investigations commenced in 2021, accompanied by further funding received in November 2024.
The primary immunotherapy candidate, OVM-200, has concluded Phase 1 clinical trials conducted within the United Kingdom and targets patients diagnosed with non-small cell lung cancer, ovarian cancer, and prostate cancer.
Trial outcomes demonstrate a favourable safety profile, a robust dual-mode immune response, and preliminary signs of therapeutic activity.
The Phase 1 investigation enrolled participants with advanced malignancies, marking the inaugural application of the ROP platform in human subjects.
Findings indicate outstanding safety characteristics and an exceptionally potent immune reaction, alongside initial observations of clinical benefit.
Regarding subsequent funding requirements, Dr Coombs noted that numerous promising avenues exist, while acknowledging the typical duration of ten to fifteen years required to advance a novel pharmaceutical compound from initial laboratory investigation through to clinical application within the United Kingdom.
The research team anticipates progressing the development programme following the favourable outcomes achieved during the Phase 1 evaluation of OVM-200.